Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus platinum-based chemotherapy versus placebo plus platinum-based chemotherapy as adjuvant treatment after complete resection of stage II-IIIB non-small cell lung cancer
CTR20222281Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Dec 2022; status: active.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222281.